CONRAY 30 SOLUTION

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

IOTHALAMATE MEGLUMINE

זמין מ:

LIEBEL-FLARSHEIM CANADA INC

קוד ATC:

V08AA04

INN (שם בינלאומי):

IOTALAMIC ACID

כמות:

300MG

טופס פרצבטיות:

SOLUTION

הרכב:

IOTHALAMATE MEGLUMINE 300MG

מסלול נתינה (של תרופות):

INTRAVASCULAR

יחידות באריזה:

100/150/250ML

סוג מרשם:

Ethical

איזור תרפויטי:

ROENTGENOGRAPHY

leaflet_short:

Active ingredient group (AIG) number: 0102763002; AHFS:

מצב אישור:

CANCELLED POST MARKET

תאריך אישור:

2018-03-14

מאפייני מוצר

_ _
_Page 1 of 40_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
CONRAY
®
30
(Iothalamate meglumine injection USP 30% w/v)
CONRAY
®
43
(Iothalamate meglumine injection USP 43% w/v)
CONRAY
®
60
(Iothalamate meglumine injection USP 60% w/v)
IONIC IODINATED RADIOGRAPHIC CONTRAST MEDIUM FOR INTRAVASCULAR USE
Liebel-Flarsheim Canada Inc.
7500 Trans-Canada Highway
Pointe-Claire, QC, H9R 5H8
CANADA
Date of Revision:
December 27,
2017
Submission Control No: 205718
_ _
_ _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
..............................................................................12
OVERDOSAGE
................................................................................................................25
ACTION AND CLINICAL PHARMACOLOGY
............................................................25
STORAGE AND STABILITY
..........................................................................................27
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................27
PART II: SCIENTIFIC INFORMATION
...............................................................................29
PHARMACEUTICAL INFORMATION
..........................................................................29
DETAILED PHARMACOLOGY
.....................................................................................30
TOXICOLOGY
.